Biotronik's new manufacturing centre for medical devices in Singapore has begun operations.
The move adds to the German company’s hubs in Europe and the US, and positions manufacturing close to growing Asia Pacific markets.
The new site includes a 1,500m2 ISO Class 7 cleanroom, supplying the global market with products for the company’s vascular intervention and cardiac rhythm management businesses.
It produces Orsiro, the world’s first hybrid drug-eluting coronary stent, along with Solia pacemaker leads.
'Singapore’s skilled workforce, excellent infrastructure and favourable business environment made it a natural choice for Biotronik as we seek to expand our global footprint,' said Erik Trip, Managing Director, Asia Pacific Manufacturing, Biotronik.
'We are building a professional team at the new site and will eventually create hundreds of new jobs in this exciting industry. This investment will support Biotronik’s dynamic growth, both in the Asia Pacific region and globally.'
The company plans to create more than 200 jobs in R&D and senior leadership roles, investing more than €20 million into operations in Singapore over the next few years.
Biotronik has been a pioneer in implantable pacemakers, defibrillators and stent therapy for more than 50 years, and has achieved double-digit revenue growth over the last decades. Its Asia Pacific headquarters have been located in Singapore since 2012.